69 Bladder cancer remains one of the most common malignancies, posing a significant challenge to healthcare systems globally. A recent study published in the BMJ highlights critical advancements in both the diagnosis and treatment of this complex disease. With an estimated 573,000 new cases and 213,000 deaths worldwide in 2020, the urgency for innovative approaches in managing bladder cancer is evident. The initial diagnosis of bladder cancer often begins with the presentation of gross hematuria, which is detected in 10-20% of patients with this symptom. Painless gross hematuria is a common indicator, though some patients may also exhibit irritative voiding symptoms like urgency, frequency, and dysuria . Cystoscopy remains the gold standard for diagnosing bladder cancer. Enhanced diagnostic techniques, such as blue light cystoscopy and narrow band imaging, are proving invaluable. These methods improve the detection rates of tumorous lesions by highlighting increased metabolic activity and vascular architecture specific to cancer tissues . Blue light cystoscopy, in particular, utilises a photosensitising agent to detect fluorescent porphyrin products in cancer cells, thereby enhancing diagnostic accuracy and reducing recurrence rates . Despite their effectiveness, the high cost and false-positive rates of these technologies are noted limitations. The management of bladder cancer varies significantly between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Approximately 70–75% of bladder cancer patients present with NMIBC at initial diagnosis. While NMIBC has high recurrence rates, progression to MIBC is less frequent but remains a serious concern. For NMIBC, the standard treatment involves transurethral resection of a bladder tumour (TURBT) followed by intravesical therapy (IVe) . Bacillus Calmette-Guérin (BCG) is the gold standard for high-risk NMIBC, reducing recurrence and progression rates significantly . Recent trials incorporating immune checkpoint inhibitors and IVe gene therapy have shown promise in further reducing recurrence and progression to MIBC. These therapies offer hope for patients, especially those unresponsive to BCG. The prognosis for MIBC is generally poorer, with about 20-25% of patients presenting with this form at diagnosis. Treatment often involves more aggressive approaches, including radical cystectomy and systemic chemotherapy. Recent advancements focus on improving patient outcomes through better surgical techniques and targeted therapies. Cisplatin-based chemotherapy remains a cornerstone for treating metastatic bladder cancer. However, the emergence of immune checkpoint inhibitors, targeted treatments, and antibody-drug conjugates is revolutionising treatment protocols. These therapies target specific genetic mutations and tumour markers, improving patient survival and quality of life. The Cancer Genome Atlas project has identified critical genetic drivers and molecular subtypes of bladder cancer, facilitating personalised treatment approaches. For instance, mutations in FGFR3 are common in NMIBC, while TP53, RB1, and PTEN mutations are associated with MIBC . Understanding these genetic alterations helps clinicians tailor treatments to individual patients, improving efficacy and reducing side effects. Bladder cancer is significantly influenced by environmental and lifestyle factors. Smoking is the most prevalent risk factor, with many patients being active smokers at diagnosis. Occupational exposures to chemicals in industries such as rubber, diesel, and painting also contribute to increased risk . Public health interventions focusing on reducing smoking rates and occupational exposures are crucial in preventing bladder cancer. In terms of epidemiology, men are disproportionately affected by bladder cancer, accounting for over three-quarters of new cases. The male-to-female incidence ratio varies by region, highlighting the need for targeted awareness and prevention strategies . The study underscores the importance of ongoing research to identify better biomarkers for early detection and more effective treatment modalities. Current efforts are focused on improving non-invasive diagnostic methods, such as molecular urine biomarkers, and developing novel therapies to enhance patient outcomes.